Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RAMM PharmaXCNQ:RAMM Days Payable is 246.10 as of Apr. 2026, which is 155% above its 10-year median of 96.51. The stock has 4 warning signs investors should review. Among 924 Drug Manufacturers companies, RAMM Pharma ranks better than 75.54% on this metric.
RAMM Pharma's average Accounts Payable for the
three
months ended in Apr. 2026 was C$0.18 Mil. RAMM Pharma's Cost of Goods Sold for the
three
months ended in Apr. 2026 was C$0.07 Mil.
Hence, RAMM Pharma's Days Payable for the
three
months ended in Apr. 2026 was 246.10.
The historical rank and industry rank for RAMM Pharma's Days Payable or its related term are showing as below:
XCNQ:RAMM'
s Days Payable Range Over the Past 10 Years
Min: 79.89 Med: 96.51 Max: 164.77
Current: 148.89
During the past 8 years, RAMM Pharma's highest Days Payable was 164.77. The lowest was 79.89. And the median was 96.51.
XCNQ:RAMM's Days Payable is ranked better than 75.54% of 924
companies
in the Drug Manufacturers industry
Industry Median: 88.845
vs XCNQ:RAMM: 148.89
RAMM Pharma's Days Payable
increased
from Apr. 2025 (93.62) to Apr. 2026 (246.10).
It may suggest that RAMM Pharmadelayed paying its suppliers.
The historical data trend for RAMM Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, RAMM Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RAMM Pharma Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RAMM Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where RAMM Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
RAMM Pharma's Days Payable for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RAMM Pharma (XCNQ:RAMM) has a Days Payable of 246.10 as of Apr. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RAMM Pharma and its competitors. This is 155% above median its historical median of 96.51. Over the past decade, RAMM Pharma's Days Payable has ranged from 79.89 to 164.77. According to the industry distribution chart, RAMM Pharma ranks #226 out of 924 companies in the Drug Manufacturers industry, placing it in the top 24.5%.
Is RAMM Pharma's Days Payable too high?
RAMM Pharma's current Days Payable of 246.10 is 155% above median its 10-year median of 96.51. Over the past 10 years, this metric has ranged from a low of 79.89 to a high of 164.77. The Drug Manufacturers industry median Days Payable is 88.85. RAMM Pharma's value of 246.10 is 177% above this industry median. Based on the distribution chart, RAMM Pharma ranks #226 out of 924 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does RAMM Pharma's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, RAMM Pharma ranks #226 out of 924 companies for Days Payable. This places RAMM Pharma in the top 25% of its industry — outperforming the majority of peers. The industry median Days Payable is 88.85. RAMM Pharma's value of 246.10 is 177% above this benchmark. Historically, RAMM Pharma's own Days Payable has ranged from 79.89 to 164.77 over the past decade. While the company's 10-year median is 96.51 vs. the industry median of 88.85, RAMM Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.85, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RAMM Pharma's current Days Payable of 246.10 is 177% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RAMM Pharma and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RAMM Pharma's current Days Payable is 246.10, which is 155% above median its own 10-year median of 96.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RAMM Pharma stock overvalued right now?
Based on GuruFocus' analysis, RAMM Pharma (XCNQ:RAMM) is currently considered Fairly Valued. The stock's GF Value™ is C$0.01, compared to a current price of C$0.01 — trading right at its estimated fair value. The current Days Payable is 246.10, which is 155% above median its 10-year median of 96.51 and 177% above the Drug Manufacturers industry median of 88.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For RAMM Pharma (XCNQ:RAMM), the current Days Payable is 246.10 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RAMM Pharma Corp is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. The group generates revenue from the sale of medical devices and consumables, the sale of pharmaceutical products, and sale of cosmetics. Geographically, it derives a majority of its revenue from Uruguay.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:RAMM has been successfully added to your 
